ArticleCancer research2009

Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.

Honglu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.